A Phase I/II, Dose-Exploration and Dose-Expansion Study Evaluating the Safety and Efficacy of Multiplex Base-Edited, Allogenic Anti-CD7 Car-T Cells BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia T-ALL or T-Cell Lymphoblastic Lymphoma T-LL
A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor MUD versus HLA-Haploidentical Related Haplo Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults AYA with Acute Leukemia or Myelodysplastic Syndrome MDS
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan GMI-1271 in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones
An Open-Label, Phase I, Multi-Center Study to Determine in Relapsed/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome or B-Cell Non-Hodgkin Lymphoma Patients the Recommended Dose of CYAD-02 After A Non-Myeloablative Preconditioning Chemotherapy Followed By A Potential CYAD-02 Consolidation Cycle for Non-Progressive Patients CYCLE-1 ? CYAD-02 NKG2D CAR-T Clinical dEvelopment
A Phase II Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway?Mutant Acute Lymphoblastic Leukemia
A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive Ph+ Acute Lymphoblastic Leukemia ALL Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy, or Who Have the T315I Mutation
Venetoclax In Combination with ASTX727, an All-ORal TherapY for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts VICTORY-MDS/MPN: a Randomized, Phase II trial